Originally published as JCO Early Release 10.1200/JCO.2008.20.8959 on October 5 2009

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Nachman, J. B. Articles by Seibel, N. L. PubMed PubMed Citation Articles by Nachman, J. B. Articles by Seibel, N. L. Related Articles Related Articles Social Bookmarking                            What's this?

Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group

From the University of Chicago Children's Hospital, Chicago, IL.

Corresponding author: James B. Nachman, MD, University of Chicago Children's Hospital, 5841 S Maryland Ave, MC 4060, Chicago, IL 60637; e-mail: jnachman{at}peds.bsd.uchicago.edu.

Purpose Patients 16 to 21 years of age with acute lymphoblastic leukemia (ALL) have an inferior outcome compared with younger children, leading some medical oncologists to advocate allogeneic stem-cell transplantation in first remission for these patients. We examined outcome for young adults with ALL enrolled onto the Children's Cancer Group (CCG) 1961 study between 1996 and 2002.

Patients and Methods CCG 1961 entered patients with ALL 1 to 21 years of age with initial WBC count 50,000/µL and/or age 10 years. Randomly assigned therapies evaluated the impact of postinduction treatment intensification on outcome. We examined outcome and prognostic factors for 262 young adults with ALL.

Results Five-year event-free and overall survival rates for young adult patients are 71.5% (SE, 3.6%) and 77.5% (SE, 3.3%), respectively. Rapid responder patients (< 25% bone marrow blasts on day 7) randomly assigned to augmented therapy had 5-year event-free survival of 81.8% (SE, 7%), as compared with 66.8% (SE, 6.7%) for patients receiving standard therapy (P = .07). One versus two interim maintenance and delayed intensification courses had no significant impact on event-free survival. WBC count more than 50,000/µL was an adverse prognostic factor.

Conclusion Young adult patients with ALL showing a rapid response to induction chemotherapy benefit from early intensive postinduction therapy but do not benefit from a second interim maintenance and delayed intensification phase. Given the excellent outcome with this chemotherapy, there seems to be no role for the routine use of allogeneic stem-cell transplantation in first remission for young adults with ALL.

See accompanying editorial on page 5121 and articles on pages 5168 and 5175

Supported by Grant No. CA 98543 from the Children's Oncology Group.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical trial information can be found for the following: NCT00002812 [ClinicalTrials.gov] .

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Articles

• Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow
  Giuseppe Basso, Marinella Veltroni, Maria Grazia Valsecchi, Michael N. Dworzak, Richard Ratei, Daniela Silvestri, Alessandra Benetello, Barbara Buldini, Oscar Maglia, Giuseppe Masera, Valentino Conter, Maurizio Arico, Andrea Biondi, and Giuseppe Gaipa
  JCO 2009 27: 5168-5174 [Abstract] [Full Text]
• Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
  Kirk R. Schultz, W. Paul Bowman, Alexander Aledo, William B. Slayton, Harland Sather, Meenakshi Devidas, Chenguang Wang, Stella M. Davies, Paul S. Gaynon, Michael Trigg, Robert Rutledge, Laura Burden, Dean Jorstad, Andrew Carroll, Nyla A. Heerema, Naomi Winick, Michael J. Borowitz, Stephen P. Hunger, William L. Carroll, and Bruce Camitta
  JCO 2009 27: 5175-5181 [Abstract] [Full Text]
• Toward a Total Cure for Acute Lymphoblastic Leukemia
  Ching-Hon Pui
  JCO 2009 27: 5121-5123 [Full Text]

This article has been cited by other articles:

				C.-H. Pui Toward a Total Cure for Acute Lymphoblastic Leukemia J. Clin. Oncol., November 1, 2009; 27(31): 5121 - 5123. [Full Text] [PDF]